Drugs / mRNA-1189
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07478952 | Mar 2026 → May 2027 expected | Epstein-Barr virus infection | ModernaTX, Inc. | Recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05164094 | Dec 2021 → Oct 2026 expected | Epstein-Barr virus infection | ModernaTX, Inc. | Active not recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT05831111 Comparator | Apr 2023 → Oct 2026 expected | Epstein-Barr virus infection | ModernaTX, Inc. | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2024-03-27 | ModernaTX, Inc. | Results Moderna Advances Multiple Vaccine Programs to Late-Stage Clinical Trials q4web.com ↗
The randomized, observer-blind, placebo-controlled study showed mRNA-1189 was immunogenic and generally well tolerated across all dose levels. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2024-03-27 | ModernaTX, Inc. | Moderna Advances Multiple Vaccine Programs to Late-Stage Clinical Trials q4web.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | mRNA-1189 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05831111 ↗ |
| Modality | Vaccine | “A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults” NCT05164094 ↗ |
| Route | Intramuscular | “3 intramuscular (IM) injections of mRNA-1189” NCT05164094 ↗ |